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Ezh2, the methyltransferase within Polycomb Repressive II Complexes, was thought to be essential for all
H3K27me3 marks in embryonic stem cells (ESCs). Recently in Molecular Cell, Shen and colleagues (2008)
revealed that EZH2 is dispensable for ESC derivation and self-renewal, and that EZH1 may unexpectedly
compensate for its loss.Polycomb proteins (PcG) are an evolu-
tionarily conserved family of chromatin
regulators known best for their function
in establishing andmaintaining epigenetic
memory during development. Polycomb
Repressive complex 2 (PRC2) consists
of three core components: enhancer of
zeste 2 (EZH2), embryonic ectoderm de-
velopment (EED), and suppressor of zeste
12 (SUZ12) (Figure 1A). The catalytic sub-
unit, EZH2, is a SET domain-containing
methyltransferase that catalyzes the for-
mation of the H3K27me3 mark, which
forms the recruiting mark for Polycomb
Repressive Complex 1 (PRC1) (Figure 1B)
thought to be the effector of PcG-medi-
ated long-term epigenetic memory (re-
viewed in Schuettengruber et al., 2007).
The involvement of PcG proteins in
maintaining ESC identity and pluripotency
was first suggested by genome-wide
studies that observed that PcG targets
are highly enriched in genes involved in
developmental patterning, morphogene-
sis, and organogenesis (Boyer et al.,
2006). Loss of EED in ESCs leads to
genome-wide and near total loss of
H3K27me3 and, consequently, the dere-
pression of PcG targets (Chamberlain
et al., 2008). Despite this dramatic reduc-
tion in H3K27Me3, ESCs can be derived
in the absence of EED. Embryos lacking
individual components of the PRC2 com-
plex, EED, EZH2, and SUZ12, survive
past implantation and die from gastrula-
tion defects 7 to 9 days postfertilization
(Faust et al., 1995; O’Carroll et al., 2001;
Pasini et al., 2007). The timing of fetal
death suggests that developmental de-
fects are responsible, rather than defi-
ciencies in the formation and/or viability
of early pluripotent cells. Consistent with
these findings, ESCs have been derivedfrom EED/ and SUZ12/ embryos
(Chamberlain et al., 2008; Pasini et al.,
2007) and are viable given the right culture
conditions. So, while PcGproteins appear
to be required for proper cell cycle in tu-
mor cells and fibroblasts (Valk-Lingbeek
et al., 2004), ESCs do not have this re-
quirement and do not require H3K27me3
marks for both establishment and self-
renewal. ESCs nonetheless require PcG
proteins for stable maintenance of the
self-renewing state, since EED/ ESCs
are prone to differentiation in culture
(Boyer et al., 2006; Chamberlain et al.,
2008). PcG proteins are also required for
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Figure 1. Alternative PRC1 and PRC2
Complexes Are Formed by Combinatorial
Assembly
(A) PRC2-Ezh2 and PRC2-Ezh1 complexes may
differ in their intrinsic methyltransferase activity or
mechanism of repression.
(B) A number of possible PRC1 complexes could
be also be formed by the combinatorial assembly
of a selection of alternative subunits.Cell Stem Cell 3ESCs to be pluripotent in the strictest
sense, i.e., give rise to all differentiated lin-
eages in a cell-autonomous fashion, since
EED/ ESCs are unable to give rise to all
cell types in in vitro differentiation assays,
and high-contribution chimeras display
developmental defects similar to knock-
out embryos (Chamberlain et al., 2008).
In a recent issue of Molecular Cell, Orkin
and colleagues demonstrate that similar
to EED and SUZ12, EZH2 is dispensable
for ESC derivation and maintenance
(Shen et al., 2008). In addition, the authors
show that similar to other mammalian
complexes regulating chromatin, such as
ATP-dependent chromatin remodeling
complexes (Wang et al., 1996), PRC2
complexes are biochemically and possi-
bly functionally diverse and that the
diversity is based on subunit assembly
(Figure 1A).
In the Orkin study, EZH2/ ESCs were
successfully derived from the inner cell
mass of EZH2/ embryos, and while
these cells displayed global loss of
H3K27me2 and -me3, the repression of
developmental genes that are known tar-
gets of PcG, evidenced by their derepres-
sion in EED/ ESCs, was surprisingly
intact (Shen et al., 2008). Finer analysis
of these key target genes revealed that
H3K27me3 was selectively maintained
at a group of key developmental targets
of PcG. This residual H3K27me3 activity
was unexpected, since EZH2 had been
thought to be the sole methyltransferase
in PRC2. In addition, the observed loss
of H3K27Me3 marks is less severe than
in the case of EED deficiency. The more
severe effect apparent in the absence of
EED may be because it is the sole gene
encoding the subunit at this position in
the PRC2 complex (Figure 1). Using, December 4, 2008 ª2008 Elsevier Inc. 577
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leagues identified noncanonical PRC2
complexes that contain EZH1, a homolog
of EZH2. Shen et al. found that EZH1 ex-
hibited methyltransferase activity in vitro
and colocalized with EED at PcG targets.
EZH1-containing complexes appear to be
selectively targeted to key developmental
genes, the repression of which may be
critical for preventing ESC differentiation.
This unanticipated capacity of EZH1
may, thus, allow it to complement the
function of EZH2-containing complexes
in repression of crucial functional genes.
Indeed, depletion of EZH1 in EZH2/
ESCs leads to the loss of H3K27me3 on
the selective PcG targets that had re-
tained the mark in the absence of EZH2,
demonstrating the functional comple-
mentation of the two proteins. However,
EZH1 and EZH2 do not appear to be com-
pletely redundant, since EZH1 cannot
complement the pluripotency defects
seen in EZH2/ ESCs, and EZH2/ em-
bryos do not survive past gastrulation.
This distinction is consistent with another
recent finding that the two genes have
very different patterns of expression, in
that EZH2, but not EZH1, is present in ac-
tively dividing cells (Margueron et al.,
2008). In addition, it is possible that the
two proteins utilize distinct mechanisms
for mediating gene repression, since the
methyltransferase activity of EZH1-PRC
complexes was shown to be very weak
in comparison to that of EZH2-PRC. In-
stead, EZH1-PRC complexes appear to
utilize an independent mechanism for
compacting and repressing chromatin578 Cell Stem Cell 3, December 4, 2008 ª20that is independent of its histone methyl-
transferase activity (Margueron et al.,
2008). However, more rigorous genetic
studies are essential in order to test the
functional differences between the two
complexes, such as complementation of
null mutants with properly expressed
transgenes or insertions of EZH1
into the EZH2 locus.
The findings of Shen et al. demonstrate
the existence of diversity in mammalian
PcG complexes via combinatorial assem-
bly of homologous subunits, which is an
emerging trend for multisubunit com-
plexes that regulate chromatin and tran-
scription. Orkin and colleagues also con-
firm the dispensability of PcG proteins in
the establishment of pluripotent cells and
in the maintenance of ESC self-renewal in
culture.
The presence of noncanonical PRC2
complexes that functionally complement
canonical complexes, but only at a selec-
tive subset of genes, raises the question
of targeting mechanisms. How are
EZH1-containing complexes selectively
targeted to specific developmental genes
whose repression is crucial for preventing
premature differentiation? Do noncanoni-
cal complexes contribute to later devel-
opmental events and, if so, to what ex-
tent? Most provocatively, ESCs lacking
Eed1 or both Ezh2 and Ezh1 have almost
no detectable H3K27Me3. Without
this modification, mutant ESCs would
be unlikely to exhibit bivalent marks (i.e.,
the coincidence of the repressing
mark, H3K27Me3, and the activating
mark, H3K4Me3) thought to be important08 Elsevier Inc.to maintain genes in a poised state for ex-
pression or repression in more differenti-
ated progeny. If not via bivalent histone
marks, what mechanisms allow genes to
remain poised in pluripotent cells for ac-
tion at a later time? The discovery that
ESCs can be generated in the virtual ab-
sence of H3K27Me3, and bivalent marks
should clear the stage for new develop-
ments in the study of the role of chromatin
in pluripotency.
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